viewFrontier IP Group PLC

Frontier IP Group - Portfolio news - Exscientia

RNS Number : 4952B
Frontier IP Group plc
31 January 2020

RNS Reach


31 January 2020



Frontier IP Group Plc

("Frontier IP" or the "Group")


Portfolio news - Exscientia: world's first clinical trials of new drug candidate created by Artificial Intelligence ("AI") started in joint development with Sumitomo Dainippon Pharma



Frontier IP, a specialist in commercialising university intellectual property, is pleased to note that  portfolio company Exscientia ("Exscientia" or the "Company"), a world leader in AI-driven drug discovery, has announced the first AI-created drug to enter clinical trials in a joint development with Sumitomo Dainippon Pharma.


A phase I clinical study of the drug candidate DSP-1181, designed to treat obsessive-compulsive disorder as an initial indication, has started in Japan.


Exscientia's other partnerships include collaborations with Bayer AG, Celgene, Sanofi, GT Apeiron, Rallybio and Evotec. Frontier IP currently holds a 3.25 per cent stake in the Company.



Exscientia statement in full:


Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial


Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) and Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) announce that a phase I clinical study of DSP-1181, that was created using Artificial Intelligence (AI), has been initiated in Japan for the treatment of obsessive-compulsive disorder as an initial indication.


DSP-1181 was created through the joint research by Sumitomo Dainippon Pharma and Exscientia, with Sumitomo Dainippon Pharma providing its experience and knowledge in monoamine GPCR drug discovery and Exscientia applying its Centaur Chemist™ Artificial Intelligence (AI) platform for drug discovery. This project was delivered by the strong synergy of the joint research, requiring less than 12 months to complete the exploratory research phase, just a fraction of the typical average of 4.5 years using conventional research techniques. ref)


DSP-1181 is being progressed as a long-acting and potent serotonin 5-HT1A receptor agonist, and its phase I clinical study to treat obsessive-compulsive disorder as an indication candidate. Through this, Sumitomo Dainippon Pharma has expanded its development pipeline to treat key unmet medical needs in the Psychiatry and Neurology area, one of the company's three focus research areas.


Toru Kimura, Board of Directors, Senior Executive Officer and Senior Executive Research Director of Sumitomo Dainippon Pharma, said: "We are very excited with the results of the joint research that resulted in the development of candidate compounds in a very short time. Exscientia's sophisticated AI drug discovery technologies combined with our company's deep experience in monoamine GPCR drug discovery, allowed us to work synergistically, delivering a highly successful outcome. We will continue to work hard to make this clinical study a success so that it may deliver new benefits to patients as soon as possible."


Andrew Hopkins, CEO of Exscientia, said: "We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery. This project's rapid success was through strong alignment of the integrated knowledge and experiences in chemistry and pharmacology on monoamine GPCR drug discovery at Sumitomo Dainippon Pharma with our AI technologies. We are proud that our AI drug discovery platform Centaur Chemist™ has contributed to generate DSP-1181 and look forward to its progression as a treatment for obsessive-compulsive disorder."




Monoamine GPCR drug discovery


Drug discovery targeting G protein-coupled receptor (GPCR), endogenous ligands of which are monoamine neurotransmitters such as serotonin, dopamine and norepinephrine


Obsessive-compulsive disorder


OCD is a psychiatric disorder characterized by the presence of obsessions (repetitive and persistence thoughts, images, or urges) and/or compulsions (repetitive behaviors or mental acts). OCD is associated with reduced quality of life as well as high levels of social and occupational impairment as a result of time-consuming (e.g., take more than 1 hour per day) by obsessions or compulsions. The mechanism of OCD has not been clarified, however dysfunction in the orbitofrontal cortex, anterior cingulate cortex, and striatum have been most strongly implicated. The number of patients in Japan and the United States is estimated to be over 1 million and around 3 million, respectively.




Paul SM et al "How to improve R&D productivity: the pharmaceutical industry's grand challenge" Nature Review Drug Discovery 2010




Exscientia statement ends 





Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk


M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)



Exscientia Limited  

Media enquires :

Mark Swindells, Chief Commercial Officer

Company website: www.exscientia.co.uk

Twitter: www.twitter.com/exscientialtd


[email protected]






[email protected]

Marianne Fekene  

+44(0) 7810298448

Camille Oster

+44(0) 7812660934






About sumitomo dainippon pharma co., ltd


Sumitomo Dainippon Pharma defines its corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide". By pouring all our efforts into the research and development of new drugs, we aim to realize our corporate mission and provide innovative and effective pharmaceutical solutions to people not only in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of Psychiatry & Neurology, Oncology and Regenerative Medicine/Cell Therapy.






About Exscientia


Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.


Exscientia's innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.


Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.


As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.


Exscientia is collaborating with several leading pharmaceutical and life sciences companies, has its headquarters in Oxford, UK with further offices in the UK, USA and Japan. For more information visit us on www.exscientia.aior follow us on Twitter @exscientialtd.





Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.


This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.








This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Frontier IP Group PLC

Price: 63

Market: AIM
Market Cap: £31.93 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Frontier IP 'in strong position' and working closely with portfolio...

Frontier IP Group PLC's (LON:FIPP) Neil Crabb speaks to Proactive London's Andrew Scott to discuss how the Intellectual property specialist's portfolio companies are adapting to the new virus threat. Crabb also touches on new investee company Elute Intelligence, in which it holds a 43% stake,...

1 day, 14 hours ago